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Results are expressed as cost per life year gained (LYG).
RESULTS: The results for a hypothetical male with a 10-year
risk of cardiovascular death of 5% are reported. Compared to
no statin the incremental cost-effectiveness ratio (ICER) of rosu-
vastatin 10mg, atorvastatin 20mg, simvastatin 80mg branded,
and simvastatin 80mg generic were €17,080/LYG, €27,090/LYG,
€36,261/LYG and €19,206/LYG, respectively. Using atorvastatin
10mg, simvastatin 40mg branded, and simvastatin 40mg-
generic reduces ICER to €20,348/LYG, €23,123/LYG and
€13,454/LYG respectively. CONCLUSION: To obtain the same
relative reduction in TC rosuvastatin 10mg seems more cost-
effective compared to atorvastatin 20mg and simvastatin 80mg.
Using higher doses of the same drug results in increased ICERs.
PCV28
ECONOMIC EVALUATION OF AN INTERDISCIPLINARY
APPROACH TO HEART FAILURE MANAGEMENT
Sutton SS1, Laws FA2, Franklin M1, Reeder CE1
1University of South Carolina, Columbia, SC, USA, 2Dorn Veterans
Hospital, Columbia, SC, USA
OBJECTIVE: To assess the utilization and costs of medical ser-
vices before and after implementation of an interdisciplinary
heart failure (HF) intervention in a Veterans Administration (VA)
setting. METHODS: Retrospective electronic chart reviews were
conducted to determine utilization and costs of medical treat-
ment for 220 patients enrolled in a HF program at a VA medical
center. Patients enrolled in the program must have been classi-
ﬁed as NYHA class III or IV (or AHA/ACC Stage C or D), and
have had at least two hospitalizations for heart failure within a
one year period prior to enrollment. A comprehensive interdis-
ciplinary management program, including physicians, nurse
practitioners, case mangers, and pharmacists, was implemented
to initiate, manage, and monitor drug therapy regimens and
patient outcomes. Utilization was measured by readmission to
the hospital. Only direct medical costs were included in the
analysis given that an institutional VA perspective was used.
Total utilization and costs for all cause readmissions for HF
patients were calculated for pre and post enrollment periods.
RESULTS: In a cohort of 220 Stage III or IV HF patients, the
average all-cause readmission rate per person per year declined
from 3.2 prior to the implementation of the HF program to 1.2
for all cause readmission post enrollment. The decrease in read-
mission rates resulted in an estimated annual savings per patient
of $11,448. CONCLUSIONS: Enrollment of Stage III and IV HF
patients in an interdisciplinary intervention program decreased
the average number of readmissions per person per year from
3.2 to 1.2 (62.5% reduction). Savings from this intervention are
estimated to be over $11,000 per HF patient per year. Further
research is being conducted to ascertain the speciﬁc effects of this
program, its contribution to operational efﬁciency, its impact on
quality of care, and its generalizability to other VA hospitals.
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OBJECTIVE: To analyze price and utilization trends for Calcium
Channel Blockers (CCB) drugs, and to compare the price differ-
ence between brand-name and generic CCB drugs over a speciﬁc
time interval. METHODS: CCB drugs with an indication for
hypertension were selected for this study. The First DataBank®
drug ﬁles and National Medicaid Pharmacy data were used to
calculate the monthly Average Wholesaler Prices (AWP), quar-
terly prescription use and reimbursement. Descriptive time-series
trend analyses were performed to assess price trends and drug
utilization patterns. The market shares were calculated as the
proportion of total number of prescriptions. RESULTS: The
average AWP per daily dose for CCBs included three tiers: 
the highest with $2 or more per day for Cardizem®, Plendil®,
and Procardia XL®, the lowest with $1 or less per day for
Isoptin® and verapamil, and middle for Norvasc ® and
Cardene®. The generic dilatizem AWP decreased from $0.84 in
1996 to $0.34 in 2004, while its brand Cardizem AWP increased
over time. Use of branded drugs (Calan®, Procardia, and
Cardizem) decreased while use of generics (verapamil, nifedip-
ine, and diltiazem) increased. The utilization of the dihydropy-
ridine CCBs (e.g. Norvasc®, Procardia®) was about two-fold
that of the non-dihydropyridine CCBs in 2004. Total expendi-
ture for brand name drugs increased from $28.87 million per
quarter in 1991 to $1.15 billion per quarter in 2004. The
market-share of Procardia ® decreased sharply from 64.26% in
1991 to 3.9% in 2001, while Norvasc® increased from 5.78%
in 1993 to 73.98% in 2004. CONCLUSIONS: The generic AWP
decreased due to competition, but there was little impact on its
brand-name AWP. Increased use of Norvasc® might be associ-
ated with its safety proﬁle. Decreased use of brand-name CCBs
might be due to Medicaid policy of generic drug use.
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OBJECTIVES: Statins are used to treat abnormal blood lipids
for reducing cholesterol and are prescribed for the elderly and
other high-risk populations. The objective of this study is to
compare drug price, cost, utilization, and market-share trends
across statin drugs in order to shed light on the effects of both
interbrand and generic competition in the market for statins.
METHODS: Using data from First DataBank, we calculated the
monthly average wholesale price (AWP) per daily dose for each
branded and generic statin drug over the period 1989–2002. We
also analyzed national Medicaid pharmacy data to construct
quarterly prescription numbers (and market shares by dividing
by total number of statin prescriptions) and per-prescription
reimbursement ﬁgures for each drug from 1991–2004.
RESULTS: Total expenditure by U.S. Medicaid programs on
statin drugs increased from $ 41.8 million in 1991 to $1.37
billion in 2003. The top three drugs reimbursed by Medicaid in
2004 included Lipitor, Zocor, and Pravachol, with market shares
of 49.0%, 29.1%, and 9.7%, respectively. Whereas Zocor,
Mevacor, and Pravachol have a relatively high AWP per daily
dose (between $4.00 and $6.50 since 1993), the AWP for Lipitor
is much lower. The rapid increase of Lipitor prescriptions was
observed from 2290 in 1st quarter 1997 to two million in 2004.
The average reimbursement per statin prescription in Medicaid
increased from $68.70 in 1991 to $101.90 in 2004. While the
generic lovastatin was introduced at two thirds the branded
AWP, there is no drop in the price of Mevacor, though Medic-
aid does face a lower cost per prescription. CONCLUSIONS:
Our results give little indication of effective interbrand competi-
tion in the statin market. Neither price nor utilization of other
branded medications falls in response to new branded entry. The
brand-name use decreased as its generic entry in Medicaid.
